| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adalimumab Plus Methotrexate versus Methotrexate Monotherapy in Early RA
|
Rizzo, Toni
|
|
2012
|
12 |
9 |
p. 16-16
|
artikel
|
| 2 |
Anti-TNF Therapy and CV Risk in RA
|
Rizzo, Toni
|
|
2012
|
12 |
9 |
p. 12-13
|
artikel
|
| 3 |
Cardiovascular Disease Impact in Rheumatic Disease
|
Rizzo, Toni
|
|
2012
|
12 |
9 |
p. 4-5
|
artikel
|
| 4 |
Clinical and Radiological Outcomes of Four DAS ≤2.4 Targeted Treatment Strategies: Eight-Year Results from the BeSt Study
|
Vinall, Maria
|
|
2012
|
12 |
9 |
p. 18-19
|
artikel
|
| 5 |
Efficacy and Safety of NNC0109-0012 (Anti-IL-20 mAb) in Patients with RA: Results from a Phase 2a Trial
|
Vinall, Maria
|
|
2012
|
12 |
9 |
p. 9-10
|
artikel
|
| 6 |
Efficacy of Different Doses of Rituximab for the Treatment of RA: Data from the CERERRA Collaboration
|
Rizzo, Toni
|
|
2012
|
12 |
9 |
p. 11-12
|
artikel
|
| 7 |
EULAR/ERA-EDTA Lupus Nephritis Recommendations
|
Rizzo, Toni
|
|
2012
|
12 |
9 |
p. 30-30
|
artikel
|
| 8 |
FREEDOM Trial Analysis: Denosumab Discontinuation and Associated Fracture Incidence
|
Rizzo, Toni
|
|
2012
|
12 |
9 |
p. 28-28
|
artikel
|
| 9 |
Guidelines for the Management of Primary Systemic Vasculitis
|
Rizzo, Toni
|
|
2012
|
12 |
9 |
p. 29-29
|
artikel
|
| 10 |
Inflammation and Fatty Degeneration in New Bone Formation in Patients with AS Treated with Anti-TNF Agents
|
Rizzo, Toni
|
|
2012
|
12 |
9 |
p. 19-20
|
artikel
|
| 11 |
Interview with the EULAR President
|
Vinall, Maria
|
|
2012
|
12 |
9 |
p. 6-6
|
artikel
|
| 12 |
LITHE Study Subset: Identification of Tocilizumab Early Response-Associated Biomarkers
|
Buckley, Rita
|
|
2012
|
12 |
9 |
p. 15-15
|
artikel
|
| 13 |
Lung Ultrasound for Screening Interstitial Lung Disease
|
Rizzo, Toni
|
|
2012
|
12 |
9 |
p. 20-20
|
artikel
|
| 14 |
Naïve to Biologic Therapy or Inadequate Responders to TNF-α Inhibitors: A Phase 2 Study of LY2439821
|
Vinall, Maria
|
|
2012
|
12 |
9 |
p. 14-15
|
artikel
|
| 15 |
One-Year Results from the AMPLE Study
|
Vinall, Maria
|
|
2012
|
12 |
9 |
p. 7-7
|
artikel
|
| 16 |
Results from the ESPOIR Cohort Study
|
Rizzo, Toni
|
|
2012
|
12 |
9 |
p. 16-17
|
artikel
|
| 17 |
Small Molecules for Rheumatoid Arthritis
|
Rizzo, Toni
|
|
2012
|
12 |
9 |
p. 26-27
|
artikel
|
| 18 |
The ASTIS Trial: First Results
|
Vinall, Maria
|
|
2012
|
12 |
9 |
p. 8-8
|
artikel
|
| 19 |
Towards Imaging Remission: Determining an MRI Inflammatory Activity-Acceptable State in RA
|
Rizzo, Toni
|
|
2012
|
12 |
9 |
p. 21-22
|
artikel
|
| 20 |
Update on ACR/EULAR RA Classification Criteria: What Have We Learned?
|
Vinall, Maria
|
|
2012
|
12 |
9 |
p. 23-25
|
artikel
|
| 21 |
24-Week Data from the Phase 4 ADACTA Trial
|
Vinall, Maria
|
|
2012
|
12 |
9 |
p. 10-11
|
artikel
|
| 22 |
24-Week Results from the RAPID-PsA Study
|
Vinall, Maria
|
|
2012
|
12 |
9 |
p. 8-9
|
artikel
|
| 23 |
12-Week Results of a Phase 2b Dose-Ranging Study of Baricitinib (LY3009104) in Combination with Traditional DMARDs in Patients with RA
|
Vinall, Maria
|
|
2012
|
12 |
9 |
p. 13-14
|
artikel
|
| 24 |
2-Year Results from the GO-RAISE Trial
|
Rizzo, Toni
|
|
2012
|
12 |
9 |
p. 17-18
|
artikel
|
Tijdschrift beschrijving